Advanced MRI imaging to diagnose and manage prostate cancer

Diffusion Histology Imaging: A Clinical Tool to Non-Invasively Diagnose and Manage Prostate Cancer

NIH-funded research Washington University · NIH-11238860

This project tests a new MRI-based method called diffusion histology imaging (DHI) to help men with elevated PSA or on active surveillance determine whether they have clinically important prostate cancer without repeated biopsies.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWashington University NIH-funded
Lab location1 site (Saint Louis, United States)
Project IDNIH-11238860 on NIH RePORTER

What this research studies

You would get a specialized MRI scan that uses a new sequence (diffusion basis spectrum imaging) and AI-style image analysis called diffusion histology imaging (DHI) to predict whether prostate tissue is cancerous and how aggressive it is. The team will apply DHI to men having an initial PSA-triggered biopsy and to men with known low-risk prostate cancer who are on active surveillance and often need repeat biopsies. Researchers will refine the DHI model using data from these groups and then test the updated model in a separate group of men undergoing PSA screening. The testing is designed to see if the method can reduce unnecessary or repeated invasive biopsies.

Who could benefit from this research

Good fit: Men with an elevated PSA facing a first prostate biopsy and men with known low-risk prostate cancer being followed with active surveillance are the ideal candidates.

Not a fit: Men with advanced or metastatic prostate cancer, prior prostate surgery or radiation, or those who cannot undergo MRI (for example, due to incompatible implants) may not benefit from this approach.

Why it matters

Potential benefit: If successful, DHI could reduce the need for invasive transrectal prostate biopsies and improve identification of men who need treatment versus surveillance.

How similar studies have performed: Preliminary data from the investigators show high accuracy for DHI in predicting biopsy results, but DHI is newer than standard multiparametric MRI and needs confirmation in larger studies.

Where this research is happening

Saint Louis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancer Patient
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.